NCT02912026View on ClinicalTrials.gov

Radiolabelled IV and Oral Metabolism Study of F901318

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 31, 2019

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

Invasive Aspergillosis

Interventions

DRUG

IV F901318

Metabolic profile AUC 0 to infinity

DRUG

Oral F901318

Metabolic profile AUC 0 to infinity

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

Sponsors

Lead Sponsor

F2G Biotech GmbH

Collaborators (1)

Quotient Clinical

All Listed Sponsors

collaborator

Quotient Clinical

OTHER

lead

F2G Biotech GmbH

INDUSTRY